01 / ATLAS
What it is
KLOW 80 is a name used for a peptide blend, not a single molecule. The visual material supplied for the atlas lists GHK-Cu, BPC-157, TB-500 and KPV. A label does not independently verify the identity or purity of the contents.
02 / ATLAS
How it works
The components appear in research on the extracellular matrix, cell migration and inflammation. Combining biological hypotheses does not demonstrate complementary effects of the blend in people. [1] [2] [3]
Read the individual entries for GHK-Cu, BPC-157, TB-500 and KPV.
03 / ATLAS
What research shows
The selected sources study individual components. In the research for this entry, we did not identify a controlled clinical trial establishing the efficacy and safety of the KLOW 80 blend.
04 / ATLAS
Study data
Indirect data: experiments on GHK-Cu and fibroblasts, BPC-157 and tendon cells, and KPV and colitis models are not tests of the KLOW 80 combination. [1] [2] [3]
We do not present clinical doses for the blend without a published, verifiable protocol. The quantity printed on a vial is not a recommended dose.
05 / ATLAS
Safety and observed adverse reactions
Each component’s safety, compatibility in the blend and interactions require separate evaluation. Missing adverse-event data for the combination do not mean that risks are absent.
06 / ATLAS
Research status
This entry covers a publicly discussed blend with insufficient clinical evidence for the exact combination. Claims about individual components do not validate the entire blend.
07 / REFERENCES
Studies and sources
- Maquart et al. · GHK-Cu in fibroblasts ↗Study of one component, not the blend
- Chang et al. · BPC-157 and tendon cells ↗Study of one component, not the blend
- Dalmasso et al. · KPV and colitis models ↗Study of one component, not the blend

